Targeting cancer stem cells in drug discovery: Current state and future perspectives

doi:10.4252/wjsc.v11.i7.398

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 7

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (13852)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

1181

WORD

425

HTML

9121

Figures (1-5)

191

Tables (1-3)

197

Sum=11115

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

277

Download

555

Sum=832

Publishing Process of This Article

Item

Count

Browse

726

Download

1179

Sum=1905

Jul 26, 2019 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (66)

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Stem Cells. Jul 26, 2019; 11(7): 398-420
Published online Jul 26, 2019. doi: 10.4252/wjsc.v11.i7.398

Table 2 Agents targeting the Notch signaling pathway in clinical trials

Compound	Target/mechanism	Tumor type	Highest phase	Organization
MK-0752	γ-secretase inhibitor	Breast cancer	Phase I	Merck
LY-900009	γ-secretase inhibitor	Metastatic cancer/lymphoma	Phase I	Perrigo and Lilly
Crenigacestat	Notch signaling inhibitor	T-cell acute lymphoblastic leukemia	Phase I/II	Lilly
CB-103	Notch signaling inhibitor	Solid tumors; hematologic cancers	Phase I/II	Cellestia Biotech
LY-3056480	Notch signaling inhibitor	Sensorineural hearing loss	Phase I/II	Lilly
RO4929097	γ-secretase inhibitor	Kidney cancer; pancreatic cancer; metastatic cancer; prostate cancer; glioblastoma multiforme; metastatic melanoma	Phase II	SpringWorks Therapeutics
BMS-906024	Notch signaling pathway	Adenoid cystic carcinoma	Phase II	Bristol-Myers Squibb
Nirogacestat	γ-secretase inhibitor	Desmoid tumors	Phase II	SpringWorks Therapeutics
Enoticumab	Anti-DLL4	Advanced solid malignancies	Phase I	Regeneron and Sanofi

Citation: Du FY, Zhou QF, Sun WJ, Chen GL. Targeting cancer stem cells in drug discovery: Current state and future perspectives. World J Stem Cells 2019; 11(7): 398-420
URL: https://www.wjgnet.com/1948-0210/full/v11/i7/398.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i7.398